Original language | English |
---|---|
Pages (from-to) | e20-e21 |
Journal | European Urology |
Volume | 79 |
Issue number | 1 |
Early online date | 2020 |
DOIs |
|
Publication status | Published - Jan 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: European Urology, Vol. 79, No. 1, 01.2021, p. e20-e21.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
TY - JOUR
T1 - Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation
AU - van Dijk, Nick
AU - Gómez de Liaño Lista, Alfonso
AU - Szabados, Bernadett
AU - Powles, Thomas
AU - van der Heijden, Michiel S.
N1 - Funding Information: Conflicts of interest: Michiel S. van der Heijden has received institutional consultancy fees from AstraZeneca/Medimmune, Roche/Genentech, BMS, Seagen and Merck/MSD, and research funding from BMS, Roche and Astellas. Thomas Powles has received consultancy fees from BMS, Pfizer, Merck/MSD, AstraZeneca, Lilly, Roche/Genentech, and Exelexis, and research funding from AstraZeneca and Roche/Genentech. Alfonso Gómez de Liaño Lista is a consultant for Roche/Genentech; has received honoraria for educational activities from AstraZeneca, BMS, Pfizer, and Roche/Genentech; and has received travel/registration expenses from Pfizer and Roche/Genentech. Nick van Dijk and Bernadett Szabados have nothing to disclose.
PY - 2021/1
Y1 - 2021/1
UR - http://www.scopus.com/inward/record.url?scp=85096568684&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.eururo.2020.10.018
DO - https://doi.org/10.1016/j.eururo.2020.10.018
M3 - Comment/Letter to the editor
C2 - 33153815
SN - 0302-2838
VL - 79
SP - e20-e21
JO - European Urology
JF - European Urology
IS - 1
ER -